Fibrocell Science Inc (FCSC)

[winduken]

You forgot to mention: demand is increasing, doctors are clamoring to sign up for training (far beyond the original projection), cost to build out manufacturing is getting much cheaper, and the few million dollars debt is trivial. They will get funded, just a question of how. At this time, even a 50% dilution will still make the future of the company attractive. Why?

Consider that an inferior product like Sculptra did about 90,000 procedures in 2009 at an average cost about 2100$. Sculptra is the best of the fillers with effect lasting close to two years and it is also slow to take effect like laViv (although a little faster if you take out the 3 months manufacturing). But, for some patients, it has severe side effects that cannot be corrected. Some doctors have stopped using it because of that possibility.

At the very least, laViv can displace Sculptra because laViv has no known important side effects beside some swelling for a few days and, anecdotally, it works for several years. Plus, with laViv patients will have the option to treat at a very cheap price other areas like fine wrinkles, all face, etc. with the same cells manufactured from the biopsy.

Then, wait for when the words are out about laViv as a natural and gradual treatment. The men market will ramp up quickly to rival the women market. This has nothing to do with vanity. A naturally youthful look is an important component for success in the workplace. The high number of men doing Sculptra (13,500 in 2009) is a good indication of that.

The future for laViv is bright. FCSC will get funding one way or the other. As they say, everything is possible but some are less probable than others. Bankruptcy is possible but with very low probability. JMO.